Medial EarlySign

Company Overview

Snapshot

Founded in January 2009 by Ori Geva and Nir Kalkstein, Medial EarlySign operated with 11–50 employees. The company raised $50 million across two funding rounds from five investors, including Horizons Ventures. In October 2025, Medial EarlySign ceased operations.

Business overview

Medial EarlySign developed AI-driven machine learning solutions to empower healthcare stakeholders in the Health Tech & Life Sciences sector. The company's advanced models derived actionable clinical insights from large datasets to improve patient outcomes, optimize diagnostics, and enhance medication management. Medial EarlySign's technology was applied to identify individuals at high risk for conditions such as non-small cell lung cancer (NSCLC), lower GI disorders and cancers, prediabetic progression to diabetes, and chronic kidney disease (CKD). The company served the healthcare industry, focusing on providers, and operated within the Digital Healthcare, Medical Decision Support, and Digital Medical Diagnostics categories.

Strategic signal

In October 2025, Medial EarlySign ceased operations. This event indicates a complete strategic shift for the company, signaling to investors and innovation teams that its AI-based clinical predictive analytics solutions are no longer actively developed or offered in the market.

Company Intelligence Q&A

What was the most recent significant corporate event for Medial EarlySign?

Medial EarlySign ceased operations in October 2025, marking a complete discontinuation of its business activities.

What was a key development for Medial EarlySign in late 2024?

In December 2024, Medial EarlySign reached a milestone with its 30th validated study published in the British Medical Journal Open Gastroenterology, highlighting the effectiveness of its ColonFlag™ algorithm for detecting colorectal cancer.

What strategic partnership did Medial EarlySign announce in October 2023?

In October 2023, Medial EarlySign partnered with Swiss pharmaceutical company Roche to utilize its AI algorithms for identifying lung cancer patients who could benefit from Roche's drug, Alecensa.

When did Medial EarlySign secure its Series B funding?

In March 2018, Medial EarlySign raised a Series B funding round from investors including aMoon Fund.

What was the focus of Medial EarlySign's collaboration with Roche in July 2022?

In July 2022, Medial EarlySign announced a strategic collaboration agreement with Roche to develop AI solutions for the early detection of lung cancer, building on an existing partnership.